Consumers Union wants action on nano-sunscreens
This article was originally published in The Rose Sheet
Executive Summary
Consumers Union, publisher of Consumer Reports, urges FDA to require safety data and transparent labeling from companies marketing nanoparticle-containing sunscreens, and to "prevent untruthful claims as to the absence of these nanoparticles." Group holds up study findings that four out of five sunscreens claiming not to contain nanoparticles actually do. Aubrey Organics Natural Sun SPF 25 Green Tea Protective Sunscreen, Badger SPF 30 Sunscreen, Kiss My Face SPF 30+ Sun Screen with Oat Protein Complex, and Mexitan SPF 30 Sunscreen are identified in Oct. 30 release. Firm says it conducted the study to see if nanoparticle-free sunscreens, which some consumers might want to buy, are actually available. "The widespread use of nanoparticles of titanium dioxide and zinc oxide in sunscreen is involving consumers in a vast experiment as to the safety of these products," says Consumers Union senior scientist Michael Hansen. Whether nanoparticles can penetrate the skin and pose a safety risk has been the subject of debate (1"The Rose Sheet" Sept. 1, 2008, p. 5)
You may also be interested in...
Consumer Effort To Unmask Nanotech Users Begs Question: Why Wear Masks?
A Consumers Union report being billed as an exposé of sunscreens that are marketed as nanotech-free but actually contain nanoparticles may signal a need not for FDA's intervention but for industry to take the lead in educating consumers on nanotechnology
Are Sunscreen Nanoparticles On Sunburned Skin More Likely To Penetrate?
An observed increase in quantum dot penetration in skin exposed to ultraviolet radiation raises concerns about commercial sunscreens that increasingly are being formulated with particles of comparable size, researchers at the University of Rochester say
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.